Disease and anatomic specificity of ethanolamine plasmalogen deficiency in Alzheimer's disease brain

Brain Research
L GinsbergN L Gershfeld

Abstract

A significant and selective deficiency of ethanolamine plasmalogen (PPE) relative to phosphatidylethanolamine was identified in post mortem brain samples from patients with Alzheimer's disease (AD). This lipid defect showed anatomic specificity, being more marked at a site of neurodegeneration in AD brain than in a region relatively spared by the disease (mid-temporal cortex vs. cerebellum) and disease specificity for AD: it was not observed at the primary site of neurodegeneration in Huntington's disease (caudate nucleus) nor Parkinson's disease (substantia nigra). PPE deficiency parallels an inherent tendency towards membrane bilayer instability previously detected in AD brain which is necessarily due to a change in membrane lipid composition, and which may contribute to AD pathogenesis.

Citations

Sep 29, 2020·Frontiers in Cell and Developmental Biology·Yulong ZhouBing Tian
Mar 28, 2017·Frontiers in Molecular Neuroscience·Marcus O W GrimmTobias Hartmann
Jan 18, 2020·Scientific Reports·Shiro MawatariTakehiko Fujino
Aug 14, 2001·The Neuroscientist : a Review Journal Bringing Neurobiology, Neurology and Psychiatry·A A Farooqui, L A Horrocks
May 20, 2011·Acta Neuropathologica·Jianqiu KouJohannes Berger
Sep 15, 2012·Journal of Neuropathology and Experimental Neurology·Noemí FabeloMario Díaz
Oct 11, 2014·Journal of Inherited Metabolic Disease·Cristina ColombelliValeria Tiranti
Feb 17, 2017·Journal of Lipid Research·Blake R HopiavuoriRobert E Anderson
Nov 28, 2015·Neuromolecular Medicine·Mohammad Jodeiri FarshbafMohammad Hossein Nasr-Esfahani
Jun 7, 2017·Journal of Alzheimer's Disease : JAD·Kevin HuynhPeter J Meikle
Feb 11, 2019·Archives of Pharmacal Research·Doo Sin Jo, Dong-Hyung Cho
Feb 27, 2020·International Journal of Molecular Sciences·Yu-Chia KaoKuen-Jer Tsai
Dec 6, 2007·Journal of Neurochemistry·Tobias HartmannMarcus O W Grimm
Feb 2, 2012·Alzheimer's Research & Therapy·Paul L Wood
Mar 2, 2011·Physiology·Paul H AxelsenIan V J Murray
Jun 11, 2008·Journal of Neurochemistry·Mushfiquddin KhanInderjit Singh
Dec 20, 2011·Experimental Brain Research·Marcus O W GrimmTobias Hartmann
Jul 12, 2013·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Paul L Wood
Mar 10, 2016·PloS One·Edith Miville-GodboutThérèse Di Paolo
Apr 11, 2014·Journal of Oleo Science·Shinji YamashitaTeruo Miyazawa
Aug 10, 2017·Nutrients·Jan Krzysztof BlusztajnTiffany J Mellott
May 20, 2017·Protein & Cell·John M Dean, Irfan J Lodhi
Aug 23, 2019·Life Science Alliance·Tomohiro KimuraRichard M Epand
Jun 17, 2020·Expert Review of Neurotherapeutics·Roberta BonomoDebra J Skene
Mar 27, 2020·Proceedings of the National Academy of Sciences of the United States of America·Ernst R WernerKatrin Watschinger
Jul 28, 2020·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Mitchel A KlingUNKNOWN Alzheimer's Disease Metabolomics Consortium (ADMC) and the Alzheimer's Disease Neuroimaging Initiative (ADNI)
Sep 18, 2020·Nature·Yilong ZouStuart L Schreiber
Jun 4, 2002·Nutritional Neuroscience·Ephraim YavinPnina Green
Oct 16, 2004·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Badreddine KriemThierry Pillot

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.